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INTRODUCTION
Fluconazole (2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-
triazol-1-yl)-2-propanol) is a triazole antifungal agent that 
has been available since 1990. Fluconazole is a broad-
spectrum triazole antifungal agent that has emerged as 
a suitable alternative to amphotericin B in the treatment 
of a wide variety of superficial and systemic fungal 
infections.1 Triazole drugs act by inhibiting the enzyme 
14-a-demethylase, which belongs to the microsomal CYP 
system; triazoles also act by blocking the biosynthesis of 
ergosterol, resulting in the accumulation of 14-a-methyl 
sterols and producing a fungistatic action. In general, 
fluconazole is well tolerated, with side effects including 
nausea, headache, skin rash, vomiting, abdominal pain, and 
diarrhea occurring during long-term therapy.2 
Excellent bioavailability has been reported after oral 
dosing, and a linear pharmacokinetics has been demonstrated 
at a dose of 200-800 mg daily. The elimination half-life 
of fluconazole ranges from 27 to 37 hours, the apparent 
volume of distribution ranges from 0.5 to 0.7 L/kg, and 
approximately 80% of unchanged drug is excreted in the 
urine.3-6 
Fluconazole is now used prophylactically in the 
management of various immune-compromised patient 
subsets1. High morbidity and mortality in patients with severe 
thermal injury were associated with fungal sepsis; thus, a 
study of the efficacy of this drug to prevent fungal sepsis in 
burn patients is necessary. It is well-known that patients with 
thermal injuries show many changes in the pharmacokinetics 
of several drugs, but data on the clinical efficacy of 
fluconazole related to its kinetics are very limited.7,8 Since 
changes in the pharmacokinetics of fluconazole are still 
unknown, it is imperative to investigate burn patients’ drug 
levels with a controlled clinical protocol.
Ana ly t i ca l  me thods  us ing  mic rob io log ica l , 
spectrophotometric, and chromatographic techniques have 
all been shown to determine fluconazole in biological 
samples. High-performance liquid chromatography (HPLC) 
is preferred due to its selectivity and the specificity of 
the assay. Methods for the determination of fluconazole 
in biological samples by HPLC-UV have been described 
previously.9-16 The objective of the present study was to 
develop a simple analytical method to determine fluconazole 
for plasma drug monitoring in patients with extensive 
thermal injury. An additional focus is its application to future 
pharmacokinetic studies. The method was validated as per 
FDA guidelines.17
MATERIALS AND METHODS
Experimental
Reagents and Chemicals
Standards of fluconazole and carbamazepine (internal 
standard) were purchased from Sigma (St. Louis, MO, USA). 
All solvents (HPLC grade), reagents for drug extraction, 
and HPLC analysis ingredients were purchased from Merck 
(Darmstadt, Germany). Purified water was obtained from 
Millipore Simplicity System (Milford, MA, USA). 
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Instrumentation
The chromatographic system consisted of a Shimadzu 
model LC-10AVP solvent delivery module (Kyoto, Japan) 
equipped with a CBM 101 controller/software Class VP, 
an autosampler (model SIL-10ADVP) and a detector (UV 
-VIS model SPD-10AVP). The peak areas were integrated 
using a Shimadzu CR6A integrator with printer/plotter. The 
analytical column was a Shimpack CN (150 x 6.0 mm, 5 
µm Shimadzu, Kyoto, Japan), with a Nova Pak C18 guard 
column (Waters Assoc., Milford, USA).
Chromatographic Conditions
The mobile phase was a mixture of purified water and 
acetonitrile (60:40 v/v), freshly prepared on the day used and 
filtered through a 0.45- (µm filter and helium degassed for 3 
minutes. The chromatographic analysis was performed in an 
isocratic system using a flow rate of 0.5 mL min-1 at room 
temperature. The injection volume was 5 µL, and the effluent 
was monitored by an ultraviolet absorbance detector at 210 
nm. A run time of 15 minutes was required to guarantee the 
selectivity of chromatographic analysis. 
Preparations of Standards and Internal Controls
The stock fluconazole solution was prepared by 
dissolving the appropriate amount of fluconazole standard 
(10 mg) in ultrapure water to reach a final drug concentration 
of 1.0 mg mL-1. Volumes of 5 mL of stock solution of 
fluconazole were transferred to a volumetric flask (50 mL). 
The higher standard (100.0 µg mL-1) was obtained by adding 
the stock solution to drug-free human plasma (blank). 
Linearity was investigated by dilution of the higher standard 
to obtain the following concentrations of fluconazole in 
plasma: 100.0, 50.0, 20.0, 10.0, 5.0, 2.0, 1.0, 0.4 and 0.2 
µg mL-1; the calibration curve across the range 0.4 - 100.0 
µg mL-1 was constructed daily. Internal quality controls 
were prepared by dilution of the stock solution in drug-free 
plasma to obtain the following high (90.0 µg mL-1), medium 
(50.0 µg mL-1) and low (1.2 µg mL-1) concentrations. 
Aliquots of 0.5 mL from plasma standards and also from the 
internal controls were distributed into Eppendorf tubes and 
stored at -20 °C until assayed.
A stock solution of carbamazepine, the internal standard 
(IS), was prepared in methanol at 1 mg mL-1; an intermediate 
solution was prepared by diluting the stock solution with 
methanol to reach the concentration 100 µg mL-1. Finally, 
the solution of the IS was prepared freshly by diluting with 
methanol to reach 20 µg mL-1. Fifty µL was then added per 
assay, and methanol was evaporated to dryness in a water 
bath before analyses.
Sample Extraction Procedure
Extraction tubes of IS (50 µL) were added, and the 
methanol was evaporated. Next, tubes containing dried IS were 
added to plasma (200 µL) and 50 µL 1.25 M sodium hydroxide, 
and the mixture was vortexed for 10 seconds. Drug extraction 
was performed by adding 3 mL dichloromethane and vortexing 
for 1 minute, following by centrifugation at 3000 rpm at 4°C 
for 30 minutes. The upper phase was aspirated and the tube 
containing the organic phase was immersed in a liquid nitrogen 
bath. The organic phase was then carefully transferred to a conic 
tube. Solvent was evaporated to dryness in a water bath under a 
nitrogen stream at 37°C. Residue was dissolved with 200 µL of 
a mixture of acetonitrile and ultrapure water (8:2 v/v), and under 
the conditions above detailed, 5 µL volumes were injected into 
the HPLC. 
Linearity, Calibration Curve and Calculation Proce-
dures 
The nominal value of fluconazole in plasma was plotted 
as a function of the peak area ratio of the internal standard 
to the drug concentration. A linear regression line was 
made, and the estimated linear correlation coefficient was 
applied to the calibration curve. At least six calibrators 
were included in the construction of the daily calibration 
curve of 0.4-100.0 µg mL-1. The daily curve was accepted 
if at least 4/6 of the internal controls (high, medium and 
low concentrations, analyzed in duplicate) presented 
systematic error lower than 15%. At least one control of 
each concentration was within the acceptable variation. Once 
accepted, the calibration curve was applied to estimate drug 
concentration in samples from patients. The linearity of the 
method was determined in triplicate for each concentration 
ranging from 0.4 to 100.0 µg mL-1
Accuracy, Precision and Recovery
The precision of the quantitative method is the degree 
of agreement among individual tests when the procedure 
is applied repeatedly to multiple replicates of three 
different concentrations. Data were expressed as the 
coefficient of variation (CV%). The intra-day precision was 
evaluated by analysis of three replicates of the high (90.0 
µg mL-1), medium (50.0 µg mL-1) and low (1.2 µg mL-1) 
concentrations. The inter-day precision was determined by 
the analysis of three replicates of the high, medium and low 
concentrations of fluconazole on three different days (n=27). 
Accuracy was evaluated by analysis of multiple 
replicates of three different concentrations and was 
expressed as percentage of inaccuracy. In some situations, 
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accuracy can be expressed as systematic error, representing 
also the recovery of each drug/assay. The parameter can 
be estimated by the value of the mean back-calculated 
concentrations divided by theoretical concentrations, 
expressed as percentage. The intra-day accuracy was 
evaluated by analysis of three replicates of the high (90.0 
µg mL-1), medium (50.0 µg mL-1) and low (1.2 µg mL-1) 
concentrations. The inter-day accuracy was determined by 
the analysis of three replicates of the high, medium and low 
concentrations of fluconazole on three different days.
Absolute recovery of fluconazole drugs from plasma was 
estimated by the peak area integrated for the drug in plasma 
versus the peak area integrated for the drug after direct 
injection of the same nominal drug concentration, expressed 
as a percentage. The efficiency of relative recovery was 
estimated by the peak area ratio integrated for each drug in 
plasma as compared to that of its internal standard. 
Specificity 
The specificity of an analytical method is its ability to 
measure accurately an analyte in the presence of endogenous 
compounds. The specificity was evaluated by the analysis 
of drug-free plasma samples (normal, hemolyzed, lipemic 
and icteric biological samples). The retention times of 
endogenous compounds were compared with those obtained 
for both fluconazole and the internal standard in the purified 
plasma extract.
Limit of Detection and Limit of Quantification
The limits of detection (LOD) and of quantification 
(LOQ) were determined based on the analysis of nine 
replicates. The LOQ was defined as the lowest plasma 
drug concentration on the calibration daily curve that could 
be determined with an accuracy of 80-120% and with a 
precision lower than 20%. The LOD was defined as 0.5 
times the limit of quantification. In addition, the LOD has a 
peak signal-to-noise ratio equivalent to 3:1, while the LOQ 
shows a ratio of 6:1.
Stability study
Study of short-term stability was performed at room 
temperature by several repetitions of a sequence of injections 
over 72 h. The study was done by testing a sequence of micro 
vials on the rack of the auto sampler containing plasma 
extracts in four different concentrations (2.2, 20.0, 50.0 and 
90.0 µg mL-1) determined on the basis of the daily curve. 
Spiked blank plasma was analyzed by HPLC after the 
clean-up of the plasma samples after three freeze/thaw cycles. 
The same sequence as detailed above was performed using 
four different concentrations (2.2, 20.0, 50.0 and 90.0 µg mL-
1) and analyzed in triplicate during three consecutive periods. 
Data were expressed as a percentage of the systematic error. 
The acceptance criterion for all concentrations studied was 
adopted at less than 10% variation. 
Robustness
The robustness of the method was determined by using 
two different columns with small changes in the proportion 
of acetonitrile in the mobile phase. The study was developed 
using two different concentrations (3 replicates each). Data 
were expressed by systematic error, as a percentage. 
Therapeutic Drug Monitoring for dose adjustment
The study was designed for drug plasma monitoring of 
fluconazole in burn patients with fungal infection plus sepsis. 
The six patients included in the study had the following 
characteristics: age: 44±15 yrs, body weight: 72.0±15.5 
kg, total burned body surface area: 32.4±25.0% (TBSA %, 
patient #1: 70%, #2: 18%, #3: 10%, #4: 53%, #5: 8%, #6: 
36%). Either the patient or the legally responsible person 
was informed in detail about the procedures to be performed 
during the treatment, and written consent was acquired. The 
protocol was approved by the ethics committee of the hospital 
Clinical Hospital, Medical School, University of Sao Paulo, 
Brazil (HC FMUSP). A sequential allocation number was 
assigned for the identification of patients; data were described 
anonymously in accordance with ethical guidelines.
Antimicrobial therapy for the control of the sepsis caused 
by MRSA was an empirically dosed regimen of vancomycin 
(2g/day, 1 hour infusion). Once the opportunistic fungal 
infection was also documented, the Hospital Committee of 
Infection recommended the inclusion of fluconazole (200 mg 
twice daily, 0.25 h infusion) in the therapy. 
Fluconazole plasma monitoring was performed in 
different periods for each patient. Blood samples (1 mL) 
were collected at the trough from the arterial catheter. Each 
blood sample was transferred to tubes (BD, Sao Paulo, 
Brazil) containing sodium EDTA, and the plasma was 
separated by centrifugation at 3000 rpm for 30 min and 
stored at -20oC until analysis. 
RESULTS
Experimental
The validation parameters for the quantification 
of fluconazole in the biological samples are shown in 
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Table 1. The specificity of the analytical method for the 
determination of fluconazole in biological samples was 
evaluated. Once endogenous compounds had been eluted 
over the first minute, no interference with the analysis was 
observed under the analytical conditions described above. 
Typical chromatograms of a blank plasma and spiked 
plasma are shown in Figure 1. The retention times were 9.3 
and 13.3 minutes for fluconazole and carbamazepine (IS), 
respectively. Peaks were monitored at 210 nm, and the total 
time required for each chromatographic run was 15 minutes 
to guarantee high selectivity and specificity. 
The analytical method exhibits excellent linearity, based 
on good recovery, and acceptable accuracy and precision 
(Table 1). Data for the linearity studies were expressed by 
the intercept and also the slope of the linear function. The 
mean, standard error of the mean (SEM) and the linear 
determination coefficient (r2) are: intercept 0.0146 (SEM: 
0.0183), slope 0.0273 (SEM: 0.0004) and r2: 0.998 over 0.4-
100.0 µg mL-1. The detection limit was 0.2 µg mL-1, and the 
quantification limit was 0.4 µg mL-1 based on the analysis of 
0.2 mL plasma in 10 replicates. 
The method showed good sensitivity, linearity and 
stability, with acceptable accuracy and precision (Table 1). In 
addition, small variations in the proportion of acetonitrile in 
the mobile phase showed acceptable precision and systematic 
error (Table 1). It should be emphasized that no robustness 
was investigated in the methods previously reported.
Analysis of the short-term stability of fluconazole (time 
and conditions of analysis) indicated no degradation of 
the drug in the plasma extract within a period up to 72 h 
while in vials on a tray of the chromatographic system. The 
short-term stability of fluconazole in plasma on the bench 
showed good precision (4.8%) and systematic error (–1.8%). 
Thaw cycles showed good stability of the drug in biological 
samples after three consecutive freeze/thaw cycles (Table 1). 
Therapeutic Drug Monitoring 
The validated bioanalytical method was applied to 
fluconazole plasma monitoring in six burn patients. Trough 
bloods drawn were obtained in different periods for each 
patient. Figure 2 shows for the six patients investigated. 
fluconazole plasma concentrations versus time during the 
follow-up period.
Table 1 - Mean confidence limits of analytical method of 
fluconazole in plasma. 
Parameter Unit Confidence Limits
Linearity (triplicate)
Linear regression (n=3 curves)
µg mL-1 0.4 – 100.0
r2 = 0.998
LOD (0.2 µg mL-1) (n=10) CV% 2.6
LOQ (0.4 µg mL-1) (n=10) CV% 3.2
Absolute recovery (n=24)
Relative recovery (n=24)
%
%
98.6 
104.2
Precision/within-day (n=9) CV% 
90.0 µg mL-1 1.44
50.0 µg mL-1 4.60
1.2 µg mL-1 3.21
Precision/between-days (n=18) CV% 
90.0 µg mL-1 0.99
50.0 µg mL-1 1.51
1.2 µg mL-1 0.74
Accuracy/within-day (n=9) % (mean+/- SD)
90.0 µg mL-1 98.1 - 100.1
50.0 µg mL-1 92.6 - 95.8
1.2 µg mL-1 101.3 – 107.5
Accuracy/between-days (n=18) % (mean+/- SD)
90.0 µg mL-1 97.6 – 100.7
50.0 µg mL-1 89.3 - 99.1
1.2 µg mL-1 103.7 – 105.1 
Stability /thawing cycles SE% 
Cycle 1(n=12) 0.06
Cycle 2(n=12) 1.65
Cycle 3(n=12) 1.22
Abbreviations: coefficient of variation (CV%), standard deviation of mean 
(SD), systematic error (SE%), higher and lower limits (mean+/-SD) for 
accuracy and precision. Symbol: r2: coefficient of determination.
Figure 1 - Chromatographic profile of fluconazole in plasma. Chromato-
grams: (A) Blank plasma. (B) Spiked blank plasma extracts Lower limit of 
detection (0.4 µg mL-1); (C) Low standard (2.2 µg mL-1) and (E) Medium 
standard (25.0 µg mL-1). (D) Plasma extract of Patient #3 (15.0 µg mL-1). 
Retention times: 9.3 min. (fluconazole) and 13.2 min (carbamazepine, 
internal standard). 
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An increase in the empirical daily dose was required for 
most patients to maintain clinical efficacy related (defined 
as a trough higher than the minimum effective concentration 
of 10 µg/mL). There was no accumulation after multiple 
infusions of the empirical dose regimen in patients #2 and 
#3, as seen by the trough lower than 1 µg/mL. Thus, their 
daily dose was increased 2-fold, from 400 mg/day (200 mg 
every 12 hrs) to 800 mg/day (200 mg every 6 hrs) to reach a 
trough higher than 10 µg/mL. The daily dose was increased 
1.5 times for patient #5 because a trough equivalent to 5 µg/
mL was obtained after the empirical daily dose. The daily 
dose was increased to 600 mg daily (200 mg every 8 hrs) for 
patient #4, but the minimum effective concentration at the 
trough was not reached.3
For patient #6, a 50% reduction in the daily dose (from 
400 mg/daily to 200 mg day) was required, as a trough 
fluconazole plasma level higher than 20 µg/mL was obtained 
after the empirical dose regimen. After the empirical dose 
regimen, patient #1 showed trough plasma levels higher than 
10 µg/mL in four consecutive periods. The high variability 
in fluconazole plasma levels obtained on days 24, 25, 27 
and 28 are probably due to changes in drug kinetics reported 
generally for antimicrobials and specifically for fluconazole 
in burn patients.18-20 
Considering the trough plasma levels for all patients 
monitored in the present study (Figure 2), dose adjustment 
was required to reach clinical efficacy in most patients due 
to failure of the empirical dose regimen (Figure 3).
 
DISCUSSION 
Analytical methods reported for the determination of 
Figure 2 - Antimicrobial therapy was started at an empirical dose regimen (fluconazole 200 mg twice daily, fast infusion) and was altered based on thera-
peutic drug monitoring of six burn patients with fungal infection. Trough plasma levels were obtained at different days after the accident. Abbreviation: 
minimum effective concentration (MEC > 10 µg/mL).
fluconazole in plasma9,12-16, serum,10,11,14 cerebral spinal fluid14 
and saliva13 have employed LC-UV after several purification 
procedures. A direct injection into the chromatographic 
system of small volumes of diluted plasma or extracts 
obtained from plasma protein precipitation showed 
serious problems related to specificity and selectivity. A 
large number of runs were required, and the reduction 
in the lifetime of the analytical column and leakage as 
a consequence of the blockade of the injector must be 
considered.10-12
Therapeutic drug monitoring of antimicrobial agents 
contributes considerably to dose adjustments and drug 
efficacy in burn patients. Problems such as blood sample 
collection in limited-access patients, and problems related 
to volume of blood drawn and the frequency of sampling 
must be solved. In addition, it is necessary that the 
analytical method have a high sensitivity for drug plasma 
Figure 3 - Dose adjustment of fluconazole to reach clinical efficacy was 
required in 5/6 burn patients with fungal infection. Antifungal therapy was 
started at the empirical dose regimen (200 mg twice daily, fast infusion). 
Data are expressed as the percentage of patients that required changes to the 
empirical dose regimen to reach clinical efficacy.
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measurement. As described in the present study, only 0.2 
mL of plasma was necessary for drug analysis. Analytical 
methods that present low sensitivity require higher plasma 
volumes (0.5 to 1.0 mL) and thus may be considered 
inadequate for fluconazole plasma measurements.9,13,14 
For the plasma purification done prior to the 
chromatographic measurement, solid-phase extraction 
(SPE) is a good option with high selectivity and sensitivity. 
Next best is the liquid-liquid extraction procedure, which is 
preferable due to its low cost compared to SPE9,13,14,16. Higher 
recovery of fluconazole was obtained by a liquid-liquid 
single extraction in an alkaline medium than in data reported 
previously.13-15 Both of the above procedures are favorable to 
plasma protein precipitation using methanol or acetonitrile.
In the present study, the analytical method used in the 
determination of fluconazole in plasma by HPLC-UV 
is quite simple, rapid and low in cost. Considering the 
selectivity, specificity, and sensitivity of the analytical 
method, the choice of the wavelength of the ultraviolet 
detector is important to guarantee the detection of low 
plasma levels accurately. A wavelength of 210 nm is 
usually applied for the detection of plasmatic fluconazole 
analyzed by LC.11-13,16 It has been suggested that 260 
nm might be a more convenient wavelength because 
nonspecific substances detected at 210 nm could be co-
eluted and consequently interfere with the area of peak 
integrated for each analyte.9,10,14-16 Nevertheless, in the 
present method, no peak of any substance was co-eluted 
with fluconazole or its internal standard; the specificity and 
selectivity of the method was good, although a peak of an 
endogenous compound was recorded in the chromatogram 
at approximately 7.5 minutes of retention time.
Concerning the chromatographic conditions for 
fluconazole plasma measurements, the separation was 
performed in a reverse-phase column and with a mixture 
of purified water plus acetonitrile as the mobile phase at 
a 0.5 mL min-1 flow rate. This method was superior to the 
analytical procedures reported previously.9-16
Compared to data reported previously, the linearity 
obtained in the present study showed a greater detectable 
range for fluconazole plasma concentrations.9,10,12,14-16 Data 
obtained in the present study were comparable to the results 
described by Koks et al., in spite of the higher plasma 
volumes required13. 
Therapeutic Drug Monitoring (TDM) 
The literature recommends ten times the minimum 
effective concentration (0.4 µg mL-1) of fluconazole for 
antifungal prophylaxis.4,6,21-24,26 However, it was reported that 
for effective pharmacotherapy of candidiasis, the fluconazole 
trough must reach 4.0 µg mL-1 at low-dose intravenous 
therapy of 100 mg a day.6,22,23 The length of the infusion 
matters; if the drug is infused over 2 hours instead of 10 
minutes, lower troughs (2.2 µg mL-1) can be expected.24 
In the present study, fluconazole plasma monitoring was 
applied to investigate six hospitalized burn patients (8-70% 
TBSA) from the Intensive Care Burn Unit. The patients 
were receiving an empirical dose regimen of 200 mg every 
12 hours (400 mg daily) for systemic fungal infection. Some 
were dose-adjusted up to 800 mg a day on the basis of the 
drug plasma monitoring. Dose adjustments of fluconazole 
to reach clinical efficacy were required in 5/6 burn 
patients with fungal infection. The dose regimen remained 
unchanged only for patient #1. The dose was increased up to 
800 mg daily for patients #2, #3, #4 and #5, but the dose was 
reduced to 200 mg daily for patient #6 due to moderate renal 
insufficiency (creatinine clearance, 40 mL/min). 
The fluconazole plasma troughs reported previously 
ranged from 20 up to 50 µg mL-1 25 or up to 70 µg mL-1 for 
high-dose therapy (800 mg day-1).26 Additionally, because the 
diffusion of the drug through the blood-brain barrier is rapid, 
drug levels in the cerebral spinal fluid (CSF) were about 70% 
of fluconazole plasma levels.22,23,26 Menichetti et al. reported 
that at high-dose therapy, the drug level in CSF is equivalent 
to 36±21 µg mL-1, and a plasma/CSF ratio of approximately 
1.0 was shown.26 On the other hand, the fluconazole trough 
ranged from 4.6 µg mL-1 to 9.0 µg mL-1 at low-dose therapy 
(200 - 400 mg daily), as reported by Cousin et al.4
Fluconazole trough plasma levels during the empirical 
dose regimen (200 mg twice daily, or 400 mg a day) in the 
first period of drug therapy were used to determine the dose 
adjustment required to reach clinical efficacy in burn patients 
investigated. The patients had a large variability in the TBSA 
registered: #1 (TBSA: 70%), #2 (18%), #3 (10%), #4 (53%), 
#5 (8%) and #6 (36%). Data obtained in the present study 
are in agreement with the results reported previously by 
Rayatt et al. based on changes in drug plasma levels as a 
consequence of kinetic changes in burn patients receiving 
the empirical dose (400 mg once daily) for the control of 
fungal infection.27 Controversially, Boucher et al. reported 
no change in the pharmacokinetics of severe burn patients 
receiving fluconazole (2-hour infusion, 400 mg every 24 
hours) on the basis of variability of burn area.20 
CONCLUSION
The method validated is simple, rapid, sensitive and 
selective, requires a low plasma volume and has acceptable 
confidence limits. It is relatively low-cost, making the 
procedure economically viable and appropriate for 
management of burn patients. The trough can be altered 
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in burn patients, probably as a consequence of important 
changes in their pharmacokinetics. This may explain 
changes in drug accumulation over time. Therapeutic drug 
monitoring will be useful in long-term antifungal therapy of 
burn patients to maintain clinical efficacy. High variability 
in plasma levels in these patients over time can be expected. 
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